Isis Pharma's (ISIS) SMA Data Seen as Important for Biogen (BIIB) Investors - Deutsche Bank
Tweet Send to a Friend
Deutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $460. Earlier its partner Isis ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
